A Phase 4 interventional study of Nuedexta (DM 20 mg/Q 10 mg) in Pseudobulbar Affect (PBA), Stroke and Dementia, sponsored by Avanir Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-15.
Sponsored by Avanir Pharmaceuticals (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,995 studies in Stroke with a site in United States — 395 open to participants now, 492 under way, 17 of them phase 3. Stroke · United States.
Among the 1,995 studies in Stroke with a site in United States, this one is the 180th largest by enrollment of the 1,621 interventional ones that give a count, is one of 84 that started in 2013, is one of 43 in phase 4, and was the 582nd registered.
8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.
Browse Stroke studies →395 of the 1,995 studies in Stroke with a site in United States are open now. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 40–85
Carle Foundation Hospital · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18–79
Neuralink Corp · Sites in United States
Ages 18+
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,995 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 236 · Phase 3 126 · Phase 4 43
First in 1980; this study’s year is marked. 84 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 367 is above the median of 48 across 6,037 interventional studies indexed under Stroke.
Median enrollment 40 across the 1,621 interventional studies, 153 across the 363 observational. Of the 1,329 that completed or were terminated, 563 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
295 of 1,995 have an industry lead sponsor. The 10 most frequent:
This study is registered under Avanir Pharmaceuticals, one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Avanir Pharmaceuticals is the lead sponsor of 13 studies on the registry; none are open to participants now.
Otsuka Holdings Co., Ltd. has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
164 of the studies in Stroke with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05047172Phase 3University of FloridaComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | 2027-01-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT05997914University of Massachusetts, WorcesterStorytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation | 2026-11 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,995 studies in Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with prevalent conditions such as dementia, stroke, and traumatic brain injury (TBI)over a 12 week period.
This will be an Open-label, Multicenter, study in patients with PBA and dementia, stroke or TBI. Patients with a clinical diagnosis of PBA and who meet all other inclusion and exclusion criteria will be eligible to participate and receive NUEDEXTA for 12 weeks.
Males and females patients with a minimum age of 18 years, a clinical diagnosis of Pseudobulbar Affect and a documented diagnosis of neurologic disease or brain injury, will be enrolled in this study.
The primary effectiveness endpoint is the mean change in the Center for Neurologic Study-Lability scale (CNS-LS). Secondary objectives include measures to evaluate treatment outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
Drug: Nuedexta (DM 20 mg/Q 10 mg)
Drug page: Dextromethorphan
Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
Also known as: Nuedexta
Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90
The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 90 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.
Time frame: Day 90 (Final visit)
Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 30
The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 30 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.
Time frame: Day 30
Mean Pseudobulbar Affect (PBA) Episode Count Per Week by Visit
PBA episode count was an investigator assessed measure in which the participant/participant's daytime caregiver was asked to identify, count and recall the total episodes of exaggerated/uncontrollable laughing or crying over the previous 7 days (prior to visit) at Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit). The response categories for this question were: 0, 1- 2, 3-5, 6-10, \>10. The original responses from participants were converted to estimate the continuous number of PBA episodes by taking the mid-point of the original response ranges and multiplying that value by 7. Data is presented as mean PBA count per week.
Time frame: Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit)
Percentage of Participants With PBA Remission
PBA remission was defined as participants with one or more episodes reported at the baseline (Day 1) visit and zero episodes reported at the Day 30 (Visit 1) or Day 90 (Final visit). Data is reported as percentage of participants with no reported episodes over the previous 7 days (prior to visit) at Day 30 (Visit 1) and Day 90 (Final visit).
Time frame: Day 30 (Visit 1) and Day 90 (Final visit)
Percentage Change From Baseline in PBA Episode Count Per Week
The change from the baseline PBA rate was measured using Mixed Effects Poisson Regression Model (adjusted for gender and age \[≤ 65 years\]).
Time frame: Day 30 (Visit 1) and Day 90 (Final visit)
Percentage of Participants With ≥ 50% Reduction in PBA Episode Count Per Week
Data is reported as the percentage of participants with ≥ 50% reduction in PBA episode count/week.
Time frame: Day 30 (Visit 1) and Day 90 (Final visit)
Percentage of Participants With ≥ 75% Reduction in PBA Episode Count Per Week
Data is reported as the percentage of participants with ≥ 75% reduction in PBA episode count/week.
Time frame: Day 30 (Visit 1) and Day 90 (Final visit)
Mean Change From Baseline in Quality of Life Visual Analog Scale (QOL-VAS) Score at Day 90
The QOL-VAS, a participant reported scale of quality of life (QOL) was used to measure the impact of PBA episodes on the participant's QOL over the previous 7 days (prior to visit) at Baseline (Day 1) and Day 90 (Final visit). The assessment was completed by a participant placing a mark on a horizontal line that extends from 0 "not (affected) at all" to 10 "significantly (affected)". The participant's mark was measured and recorded at each time point. The change in QOL-VAS score from baseline to day 90 visit, defined as the day 90 score minus the baseline score, was analyzed. Data is reported as mean QOL-VAS score; a positive change in score represented an increase in participant's quality of life.
Time frame: Day 90 (Final visit)
Percentage of Participants With Clinical Global Impression-Change (CGI-C) Score at Day 90
CGI-C, an investigator-assessed scale was used to measure the overall treatment response. CGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with CGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.
Time frame: Day 90 (Final visit)
Percentage of Participants With Patient Global Impression-Change (PGI-C) Score at Day 90
PGI-C, a participant/participant's caregiver-assessed scale was used to measure participant overall treatment response. PGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with PGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.
Time frame: Day 90 (Final visit)
Percentage of Participants With Treatment Satisfaction Survey
The treatment satisfaction survey was a 5 point single question survey that was administered by the site staff to the participant/participant's caregiver. Participants were asked to rate their response to treatment satisfaction as: very dissatisfied, somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, and very satisfied. Data is presented as percentage of participants with treatment satisfaction at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.
Time frame: Day 90 (Final visit)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs (defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) and SAEs (defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening \[ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death\], required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug) were assessed during the study.
Time frame: From signing of informed consent up to 30 days after receiving the last dose of study drug or up to approximately 120 days
| Milestone | Dextromethorphan Hydrobromide 20 mg + Quinidine Sulfate 10 mg |
|---|---|
| Started | 367 |
| Completed | 271 |
| Not completed | 96 |
| Withdrew: Adverse event | 34 |
| Withdrew: Withdrawal by subject | 21 |
| Withdrew: Death | 2 |
| Withdrew: Investigator decision | 4 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Other | 15 |
The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 90 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.
| Units on a scale | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 90 | -7.69 ± 6.07 | -7.22 ± 6.04 | -7.59 ± 6.67 | -8.54 ± 5.18 |
The CNS-LS was a seven-item, self-administered questionnaire, completed by the participant or participant's caregiver that provided a quantitative measure of the perceived frequency and severity of Pseudobulbar Affect (PBA) episodes. It consisted of two subscales measuring labile laughter (four items) and labile crying (three items). Each item was rated on a scale from 1 (applies never) to 5 (applies most of the time). The total score was calculated as the sum of the item values that resulted in a score ranging from 7 (no symptoms) to 35 (maximum symptom severity and frequency). A single continuous variable was created for the reported time point. The change in CNS-LS was calculated as the score from the Day 30 assessment minus the Baseline CNS-LS measure. A negative change represented a decrease in CNS-LS score over time following the baseline assessment indicating a perceived decrease in frequency and severity of PBA episodes.
| Units on a scale | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Mean Change From Baseline in Center for Neurologic Study-Lability Scale (CNS-LS) Score at Day 30 | -5.43 ± 5.52 | -4.60 ± 5.08 | -6.17 ± 6.12 | -5.58 ± 5.21 |
PBA episode count was an investigator assessed measure in which the participant/participant's daytime caregiver was asked to identify, count and recall the total episodes of exaggerated/uncontrollable laughing or crying over the previous 7 days (prior to visit) at Baseline (Day 1), Day 30 (Visit 1), and Day 90 (Final visit). The response categories for this question were: 0, 1- 2, 3-5, 6-10, \>10. The original responses from participants were converted to estimate the continuous number of PBA episodes by taking the mid-point of the original response ranges and multiplying that value by 7. Data is presented as mean PBA count per week.
| Count/week | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Baseline | 21.33 ± 24.97 | 25.68 ± 23.06 | 19.62 ± 29.62 | 17.94 ± 20.31 |
| Day 30 (n= 296, 108, 102, 86) | 9.10 ± 14.29 | 12.85 ± 16.80 | 6.95 ± 11.83 | 6.94 ± 12.60 |
| Day 90 (n= 260, 102, 92, 66) | 6.23 ± 11.45 | 8.41 ± 14.26 | 5.26 ± 9.60 | 4.20 ± 8.02 |
PBA remission was defined as participants with one or more episodes reported at the baseline (Day 1) visit and zero episodes reported at the Day 30 (Visit 1) or Day 90 (Final visit). Data is reported as percentage of participants with no reported episodes over the previous 7 days (prior to visit) at Day 30 (Visit 1) and Day 90 (Final visit).
| Percentage of participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Day 30 (n= 296, 108, 102, 86) | 20.3 | 13.0 | 22.5 | 26.7 |
| Day 90 (n= 260, 102, 92, 66) | 35.4 | 31.4 | 34.8 | 42.4 |
The change from the baseline PBA rate was measured using Mixed Effects Poisson Regression Model (adjusted for gender and age \[≤ 65 years\]).
| percent change | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Day 30 (n= 296, 108, 102, 86) | -57.5 (-59.3 to -55.5) | -50.0 (-53.1 to -46.6) | -64.9 (-67.7 to -61.7) | -61.3 (-64.8 to -57.7) |
| Day 90 (n=260, 102, 92, 66) | -72.3 (-73.8 to -70.8) | -67.7 (-70.1 to -65.1) | -74.5 (-76.9 to -71.8) | -78.5 (-81.2 to -75.7) |
Data is reported as the percentage of participants with ≥ 50% reduction in PBA episode count/week.
| Percentage of participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Day 30 (n= 289, 107, 100, 82) | 63.7 | 58.9 | 65.0 | 68.3 |
| Day 90 (n= 254, 101, 90, 63) | 78.0 | 76.2 | 76.7 | 82.5 |
Data is reported as the percentage of participants with ≥ 75% reduction in PBA episode count/week.
| Percentage of participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Day 30 (n= 289, 107, 100, 82) | 42.2 | 33.6 | 42.0 | 53.7 |
| Day 90 (n= 254, 101, 90, 63) | 57.1 | 57.4 | 47.8 | 69.8 |
The QOL-VAS, a participant reported scale of quality of life (QOL) was used to measure the impact of PBA episodes on the participant's QOL over the previous 7 days (prior to visit) at Baseline (Day 1) and Day 90 (Final visit). The assessment was completed by a participant placing a mark on a horizontal line that extends from 0 "not (affected) at all" to 10 "significantly (affected)". The participant's mark was measured and recorded at each time point. The change in QOL-VAS score from baseline to day 90 visit, defined as the day 90 score minus the baseline score, was analyzed. Data is reported as mean QOL-VAS score; a positive change in score represented an increase in participant's quality of life.
| Units on a scale | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Mean Change From Baseline in Quality of Life Visual Analog Scale (QOL-VAS) Score at Day 90 | -3.13 ± 3.21 | -3.20 ± 2.98 | -2.66 ± 3.35 | -3.67 ± 3.29 |
CGI-C, an investigator-assessed scale was used to measure the overall treatment response. CGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with CGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.
| Percentage of participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Very much improved | 33.7 | 30.4 | 33.0 | 39.7 |
| Much improved | 42.9 | 47.1 | 41.8 | 38.2 |
| Minimally improved | 13.4 | 13.7 | 14.3 | 11.8 |
| No change | 8.8 | 8.8 | 7.7 | 10.3 |
| Minimally worse | 0.8 | 0.0 | 2.2 | 0.0 |
| Much worse | 0.4 | 0.0 | 1.1 | 0.0 |
| Veru much worse | 0.0 | 0.0 | 0.0 | 0.0 |
PGI-C, a participant/participant's caregiver-assessed scale was used to measure participant overall treatment response. PGI-C, a 7-point (1-7) scale was rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. Data is presented as percentage of participants with PGI-C score at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.
| Percentage of participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Very much improved | 32.6 | 28.4 | 33.7 | 37.3 |
| Much improved | 39.8 | 48.0 | 33.7 | 35.8 |
| Minimally improved | 18.8 | 14.7 | 21.7 | 20.9 |
| No change | 8.0 | 7.8 | 10.9 | 4.5 |
| Minimally worse | 0.4 | 1.0 | 0.0 | 0.0 |
| Much worse | 0.4 | 0.0 | 0.0 | 1.5 |
| Veru much worse | 0.0 | 0.0 | 0.0 | 0.0 |
The treatment satisfaction survey was a 5 point single question survey that was administered by the site staff to the participant/participant's caregiver. Participants were asked to rate their response to treatment satisfaction as: very dissatisfied, somewhat dissatisfied, neither satisfied nor dissatisfied, somewhat satisfied, and very satisfied. Data is presented as percentage of participants with treatment satisfaction at Day 90. Percentages within a measure may not sum to 100.0 due to rounding. Percentages use the count of participants with non-missing data as the denominator.
| Percentage of participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Very dissatisfied | 7.7 | 4.9 | 12.0 | 6.0 |
| Somewhat dissatisfied | 5.4 | 6.9 | 5.4 | 3.0 |
| Neither satisfied nor dissatisfied | 11.5 | 13.7 | 8.7 | 11.9 |
| Somewhat satisfied | 28.0 | 21.6 | 31.5 | 32.8 |
| Very satisfied | 47.5 | 52.9 | 42.4 | 46.3 |
AEs (defined as any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product) and SAEs (defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening \[ie, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death\], required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was as a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug) were assessed during the study.
| Participants | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| AEs | 132 | 49 | 40 | 43 |
| SAEs | 23 | 14 | 5 | 4 |
Collected over From signing of informed consent up to 30 days after receiving the last dose of study drug or up to approximately 120 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall | — | 23/367 (6.3%) | 35/367 (9.5%) |
| Dementia | — | 14/134 (10.4%) | 15/134 (11.2%) |
| Stroke | — | 5/113 (4.4%) | 9/113 (8%) |
| Traumatic Brain Injury | — | 4/120 (3.3%) | 11/120 (9.2%) |
| Event | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 3/367 | 1/134 | 0/113 | 2/120 |
| Non-cardiac chest painGeneral disorders | 1/367 | 0/134 | 1/113 | 0/120 |
| PneumoniaInfections and infestations | 1/367 | 0/134 | 1/113 | 0/120 |
| Facial bones fractureInjury, poisoning and procedural complications | 1/367 | 0/134 | 1/113 | 0/120 |
| FallInjury, poisoning and procedural complications | 2/367 | 1/134 | 1/113 | 0/120 |
| Carotid artery stenosisNervous system disorders | 1/367 | 0/134 | 1/113 | 0/120 |
| Transient ischaemic attackNervous system disorders | 1/367 | 0/134 | 1/113 | 0/120 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/367 | 0/134 | 1/113 | 0/120 |
| Myocardial infarctionCardiac disorders | 1/367 | 0/134 | 0/113 | 1/120 |
| Prostate infectionInfections and infestations | 1/367 | 0/134 | 0/113 | 1/120 |
| Event | Overall | Dementia | Stroke | Traumatic Brain Injury |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 20/367 | 5/134 | 5/113 | 10/120 |
| HeadacheNervous system disorders | 15/367 | 10/134 | 4/113 | 1/120 |
| Age, Categorical(Participants) | Dextromethorphan Hydrobromide 20 mg + Quinidine Sulfate 10 mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 215 |
| >=65 years | 152 |
| Sex: Female, Male(Participants) | Dextromethorphan Hydrobromide 20 mg + Quinidine Sulfate 10 mg |
|---|---|
| Female | 202 |
| Male | 165 |
The record gives a start of Feb 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextromethorphan